Evidence map›Paper›PMID 40951899›Full record

ArticleJournal of medical biochemistry2025

Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.

Tinghuan Wang, Fei Wang, Xinglu Dong, Xiaofeng Liu, Zhiyu Cui, Yingshuai Shi

Abstract read
In one paragraph

Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tinghuan WangThe First People's Hospital of Jiashan, Department of Neurology, Jiaxing, Zhejiang, China.
Fei WangThe First People's Hospital of Jiashan, Department of Neurology, Jiaxing, Zhejiang, China.
Xinglu DongThe First People's Hospital of Jiashan, Department of Neurology, Jiaxing, Zhejiang, China.
Xiaofeng LiuThe First People's Hospital of Jiashan, Department of Neurology, Jiaxing, Zhejiang, China.
Zhiyu CuiThe First People's Hospital of Jiashan, Department of Neurology, Jiaxing, Zhejiang, China.
Yingshuai ShiThe First People's Hospital of Jiashan, Department of Neurology, Jiaxing, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To explore the Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in patients receiving butylphthalide and sodium chloride injection in combination with atorvastatin calcium in acute cerebral infarction patients. Methods: Eighty ACI patients treated at our hospital between January 2022 and January 2024 were included as study participants, followed by divided into the control group (CG) and study group (SG). The CG was given atorvastatin calcium tablets. Based on the CG, the SG received a butylphthalide sodium chloride injection. The clinical efficacy, neurological impairment, daily living ability, hemorheological indicators, neurobiochemical indicators, and occurrence of adverse reactions in the two groups were compared. Results: Compared to the CG, the SG's total effective clinical effect rate was significantly higher (P<0.05). After therapy, the NIHSS score in the SG showed a significant reduction relative to the CG, and the BI score in the SG was significantly higher relative to the CG (P<0.05). The whole blood high shear viscosity, whole blood low shear viscosity, PV, HCT, and FIB levels in the SG, were significantly reduced relative to the CG (P< 0.05). The improvements of BDNF NSE, and GFAP levels in the SG were significantly superior to the CG (P< 0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05). Conclusions: The combination of butylphthalide sodium chloride injection and atorvastatin calcium tablets significantly improved clinical outcomes in ACI patients by improving neurological function, daily living ability, cerebral hemodynamics, and neurobiochemical markers. This therapeutic regimen offers a promising approach to ACI management and warrants further clinical promotion. The novel aspect of this study lies in its comprehensive evaluation of both neurological and hemodynamic improvements, highlighting the potential synergistic benefits of this combined therapy.

Indexed as

acute cerebral infarctionatorvastatin calcium tabletsbutylphthalide and sodium chloride injectionglial fibrillary acidic protein (GFAP)neurological impairmentneuron-specific enolase (NSE)serum brain-derived neurotrophic factor (BDNF)

Identifiers

PMID40951899
PMCPMC12433302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.